DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0261006 A1 HAKOZAKI Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0261006 A1 HAKOZAKI Et Al US 20130261 006A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0261006 A1 HAKOZAKI et al. (43) Pub. Date: Oct. 3, 2013 (54) METHOD OF GENERATINGA Publication Classification HYPERPGMENTATION CONDITION GENE EXPRESSION SIGNATURE (51) Int. Cl. CI2O I/68 (2006.01) (71) Applicant: THE PROCTER & GAMBLE (52) U.S. Cl. COMPANY, Cincinnati, OH (US) CPC .................................... CI2O I/6881 (2013.01) USPC ................................................. 506/7:506/16 (72) Inventors: Tomohiro HAKOZAKI, Cincinnati, OH (US); Wenzhu ZHAO, Mason, OH (57) ABSTRACT (US); Robert Lloyd BINDER, A method of generating a hyperpigmentation condition gene Montgomery, OH (US); Jun XU, Mason, expression signature for use in identifying connections OH (US) between perturbagens and genes associated with a skin pig mentation condition. The method includes providing a gene Assignee: The Procter & Gamble Company, expression profile for a reference sample of human skin cells (73) not affected with a pigmentation condition; generating a gene Cincinnati, OH (US) expression profile for a sample of human skin cells from a Subject exhibiting the hyperpigmentation condition; compar (21) Appl. No.: 13/851,873 ing the expression profiles to determine a gene expression signature that includes a set of differentially expressed genes; (22) Filed: Mar. 27, 2013 assigning an identifier to each gene constituting the gene expression signature and ordering the identifiers according to the direction of differential expression to create one or more Related U.S. Application Data gene expression signature lists; and storing the one or more (60) Provisional application No. 61/618,115, filed on Mar. gene expression signature lists on at least one computer read 30, 2012. able medium. Patent Application Publication Oct. 3, 2013 Sheet 1 of 73 US 2013/026100.6 A1 FIG. : Table A Pigmentation control targets and some Benchmark Agents Pigmentation Control Target Effective Agent Examples Examples Tyrosinase inhibition Hydroquinone, resorcinols, koic acid, arbutin, deoxy-arbutin, ascorbic acid (vitamin C) Tyrosinase copper chelation Ellagic acid, kojic acid Inhibition of tyrosinase Glucosamine, N-acetylglucosamine, tunicamycin Melanosome transfer Niacinamide, protease inhibitors Inhibit binding of alpha-MSH to N-undecylenoyl-phenylalanine melanocyte Down regulation of tyrosinase Retinoid (trans-retinoic acid, retino and its esters, retinaldehyde) Antioxidant Vitamin C compounds, vitamin E, sulfhydryl compounds Anti-inflammatory agent Hydrocortisone, phytosterol, glycyrrhetinic acid, tranexamic Increase epidermal turnover acid,Retinoids, chamomile salicylic extract acid, alpha-hydroxy acids, alpha-keto... .............. acids, -- adenosine monophosphate Patent Application Publication Oct. 3, 2013 Sheet 2 of 73 US 2013/026100.6 A1 FIG. 2: TABLES B and C 20745 at 214333 x isocitrate dehydrogenase 3 (NAD+) gamma 207365 x a ubiquitin specific peptidase 34 202396 at TCERC ption elongation regulator 1 20358 at LYST sosomal trafficking regulator ochondrial ribosomal protein L34 / Dutt 7U.4 u.uu J asein kinase I, gamma 2 -AL530441 0. eli division cycle 42 (GTP binding protein, 25kDa) M35543 ansducer of ERBB2, - - - - - - - - - - - - - - - - - v-- . v. - - - - - M. v.- - - - - - - - - - - - - - - - - - - - - - - - - - - W - - - - - -v- W --w---mus ----------v-u------ SRY (sex determining region Y)-box 15 217759 at tripartite motif-containing 44 216859 x 212254s at DST 211464 x at CASP6 206765 at KC 200055 at TAF10 associated factor 30kDa 21 0547 x at ICA .-- -- islet cell autoantigen 1. 69kDa -3- 201471 sat SQSTM1 205555 s at MSX2 212143 NM_002847.0.00396 214715. nc finger protein 160 m---------...-- ------------m-m-r-...- kelch domain containin g 4. 8-M.----- ------------------- testis derived transcript (3 LIM domains) M_015641000474 202720 at 202178 at M_002744 000500 22076 is at TAOK3 NM_016281 000500 : BF439472 000503 Patent Application Publication Oct. 3, 2013 Sheet 3 of 73 US 2013/026100.6 A1 224.54 x Heterogeneous nuclear ribonucleoprotein D-like r protein 24 NM_016623.000539 202468 is - N Ll catenin (cadherin-associated protein), alpha-like 1 ---m 22 1737 at guanine nucleotide binding protein (G protein) alpha 12 '. 0.005 S1 like ( yeast) homeobox D4 mu- -- - - - -m-, -- upstream binding protein (LBP-1a) sulin-like growth factor binding protein 3 M31159 000592 FKIAA 1598 . 'S''' - '''S'm ' protein kinase, AMP-activated, beta 2 non-catalytic subunit eroxisome biogenesis factor l marylacetoacetate hydrolase domain containing 2B enase (lipoamide) alpha 1 integrin, beta (fibronectin receptor, beta polypeptide, antigen CO29 includes MDF2, MSK12) BG500301 O.00649. 201227s at NDUFB8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19kDa NM_005040.00652 220602_s at s solute carrier familymm mm. 2 (facilitated glucose/fructose transporter), NM_0250840.00652. member 5 ' ' ' ' ' ' ' ' ' m arbonyl reductase 3. poly (ADP-ribose) polymerase family, member 2 guanine nucleotide binding protein-like 3 (nucleolar) line 1 (Opitz/BBB syndrome) hromosome 5 open reading frame 13 -u-m-m-m-m-m-m-r ------ golgi associated, gamma adaptin ear containing, ARF binding protein asparaginyl-tRNA synthetase etallothionein pseudogene 3 219231 at methylguanosine synthase homolog (S. cerevisiae) 215228 at scient helix loop helix 2 2 9790s at NPR3 peptide receptor C) NM_0009080.00821 ter-rig-r---210424s at GOLGA8A golgi autoantigen, golgin subfamily a 8A AF163441 000827. 210424s at GOLGA8B golgi autoantigen, golgin subfamily a, 8B AF16344 0.00827. sema domain, immunoglobulin domain (g), transmembrane domain (TM) and short cytoplasmic domain. (semaphorin) 4C M_017789 000835 slocated promoter region (to activated MET oncogene) 'WWW K0231. 209306 s a SWAP70. SWAP-70 protein-------------------------------------------------------------------------------------------------------------------------------------------------------------- A1139569-------------------------------- 000837 Patent Application Publication Oct. 3, 2013 Sheet 4 of 73 US 2013/0261006 A1 ise (STE24 homolog, S. cerevisiae) 857 000853. 0.00858 c fin ger protein 57 pindlin family, member 2B indlin family, member 2A F356353 000886. sprouty homolog4 (Drosophila) WA8843 0.00898 zinc finger and BTB domain containing 1 0.00899 ctin filament) muscle ine, alpha - apoptotic chromatin condensation inducer 1 t CCDC101 coiled-coil domain containing 101 OX4 -- SRY (sex determining region Y)-box 4. BG528420 000 201810 sat SH3BP5 SH3-domain binding protein 5 (BTK associated) AL562152 000931 221 188s at CIDEB cell death-inducing DFFA-like effector b 213140 s at SS18Ll ----- synovial sarcoma translocation gene on chromosome 18-like 1 i 218612 s at TSSC4 - tumor suppressing subtransferable candidate 4 - transcription factor AP-2 gamma (activating enhancer binding i 205286 at protein 2 gamma) U85658 ------------(),00978 let cell autoantigen 1 , 69kDa w- V 004968 0.00978 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 200639_s_at YWHAZ tactivation protein, Zeta polypeptide 201804 x at TBCB tubulin folding cofactor B actor VIII associated (intronic transcript) 220051 at PRSS21 protease, serine, 21 (testisin) 21.0153 s at ME2 malic enzyme 2, NAD(+)-dependent, mitochondrial 202123 s at bl Abelson murine leukemia viral oncogene homolog 1 20701 lSat PTK7 protein tyrosine kinase 7 r scaffold homolog (S. cerevisiae) NM_015700 001083 polymerase (DNA directed), gamma 2, accessory subunit NM_007215 001108 - - omain containing 4B 01 126 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F , ticulocalbin 3, EF-hand calcium binding domain ---------------------------- ------------------------- -------------- desmocollin 2 domain family. member 2 protocadherin 7 Patent Application Publication Oct. 3, 2013 Sheet 5 of 73 US 2013/0261006 A1 homeobox D1 ondin 2, extracellular matrix protein dicarbonyl/L-xylulose reductase NM_016286001188. leoporin 43kDa NM_0246470.01 195 222136 x at ZNF43 zinc finge - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ----------------------- 217752 s at CNDP2 CNDP dipeptidase 2 (metallopeptidase M20 family) 204078------------------- at SC65 --------------------------------------------synaptonemal complex - protein------------ SC65 microtubule associated monoxygenase, calponin andLIM domain ----...- ...-- | ------- 218376 sat MICAL1 containing NM_022765 0.01.237 208820207060 at PTK2EN2 engrailedPTK2 protein homeobox2 tyrosine kinase 2 - A057,3900279M001427. ---202265 - - - - - - - - - - - - - - - at BMI1 polycomb ring finger oncogene ... --. zinc finger protein 419 219826-------------------- at M_02469100.335 RRP9, small subunit (SSU) processome component, homolog (yeast) - M-004704001341 rf34 chromosome I open reading frame 34 C004399 001353 221974 at - IIIPW Imprinted in Prader-Willi syndroine w770748 00135 amyloid beta (A4) precursor protein-binding, family A, member 210720s at APBA2BP binding protein AB039947 0.01365; 204525 at PHF14 PHD finger protein 14 NM_014660 001366 rimatogenesis associated g protein 1 (liprin beta1) 200775 s at HNRPK heterogeneous nuclear ribonucleoprotein K i golgi associated, gamma adaptin ear containing, ARF binding GAI :protein RNA, cDNA DKFZp547C126 (from clone DKFZp547C126). AL3595 215828 ---------------------------------- --------------------------------...-as-------------------------------------------------------. 211609 x SMD4 proteasome (prosone, macropain)26S subunit, non-ATPase, 4, U5 1007 0.01444------------- 43977 at
Load more

Recommended publications
  • United States Patent ( 10 ) Patent No.: US 10,468,120 B2 Hakozaki Et Al
    US010468120B2 United States Patent ( 10 ) Patent No.: US 10,468,120 B2 Hakozaki et al. (45 ) Date of Patent : * Nov . 5 , 2019 (54 ) METHOD OF GENERATING A 2008/0280844 A1 * 11/2008 Lessnick C12Q 1/6886 HYPERPIGMENTATION CONDITION GENE 514/44 A 2009/0017080 A1 1/2009 Tanner et al. EXPRESSION SIGNATURE 2010/0189669 A1 * 7/2010 Hakozaki 424/60 2010/0292085 A1 * 11/2010 Lum GOIN 33/5067 (71 ) Applicant: The Procter & Gamble Company , 506/7 Cincinnati, OH (US ) 2011/0150798 A1 6/2011 Bacus 2011/0269852 A1 * 11/2011 McDaniel 514/789 ( 72 ) Inventors: Tomohiro Hakozaki, Cincinnati, OH 2012/0149773 A1 * 6/2012 Park A61K 31/203 (US ) ; Wenzhu Zhao , Mason , OH (US ) ; 514/552 Robert Lloyd Binder , Montgomery, 2013/0165470 A1 * 6/2013 Isfort A61K 31/439 OH (US ) ; Jun Xu , Mason , OH (US ) 514/289 (73 ) Assignee : The Procter & Gamble Company , FOREIGN PATENT DOCUMENTS Cincinnati , OH (US ) WO WO 2003/100557 12/2003 WO WO 2005/040416 5/2005 ( * ) Notice : Subject to any disclaimer, the term of this WO 2012011904 A1 1/2012 patent is extended or adjusted under 35 WO 2012116081 A2 8/2012 WO WO2012116081 8/2012 U.S.C. 154 ( b ) by 162 days . WO WO 2014/028572 2/2014 This patent is subject to a terminal dis claimer. OTHER PUBLICATIONS ( 21) Appl. No .: 13 /851,873 Affymetrix HGU133A 2.0 ( release 33 , submitted Oct. 30 , 2012 ) , Affymetrix.com . * Filed : Hakozaki et al. ( 2002 )British Journal of Dermatology 147.1 (2002 ) : ( 22 ) Mar. 27 , 2013 20-31 . * Aoki et al . (British Journal of Dermatology 156.6 (2007 ) : 1214 (65 ) Prior Publication Data 1223 ) .
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Identification of Proteins That Are Differentially Expressed in Brains
    Journal of Proteomics 139 (2016) 103–121 Contents lists available at ScienceDirect Journal of Proteomics journal homepage: www.elsevier.com/locate/jprot Identification of proteins that are differentially expressed in brains with Alzheimer's disease using iTRAQ labeling and tandem mass spectrometry Benito Minjarez a,1, Karla Grisel Calderón-González a, Ma. Luz Valero Rustarazo b,2, María Esther Herrera-Aguirre a,MaríaLuisaLabra-Barriosa, Diego E. Rincon-Limas c,d, Manuel M. Sánchez del Pino b,3,RaulMenae,4, Juan Pedro Luna-Arias a,⁎ a Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (Cinvestav-IPN), Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Gustavo A. Madero, C.P. 07360 Ciudad de México, México b Unidad de Proteómica, Centro de Investigación Príncipe Felipe, C/Rambla del Saler 16, 46012 Valencia, España c Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA d Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA e Departamento de Fisiología, Biofísica y Neurociencias, Cinvestav-IPN, Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Gustavo A. Madero, C.P. 07360 Ciudad de México, México article info abstract Article history: Alzheimer's disease is one of the leading causes of dementia in the elderly. It is considered the result of complex Received 5 November 2015 events involving both genetic and environmental factors. To gain further insights into this complexity, we Received in revised form 26 February 2016 quantitatively analyzed the proteome of cortex region of brains from patients diagnosed with Alzheimer's Accepted 11 March 2016 disease, using a bottom-up proteomics approach.
    [Show full text]
  • Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The high mortality rate of gastric cancer (GC) is in part due to the absence of initial disclosure of its biomarkers. The recognition of important genes associated in GC is therefore recommended to advance clinical prognosis, diagnosis and and treatment outcomes. The current investigation used the microarray dataset GSE113255 RNA seq data from the Gene Expression Omnibus database to diagnose differentially expressed genes (DEGs). Pathway and gene ontology enrichment analyses were performed, and a proteinprotein interaction network, modules, target genes - miRNA regulatory network and target genes - TF regulatory network were constructed and analyzed. Finally, validation of hub genes was performed. The 1008 DEGs identified consisted of 505 up regulated genes and 503 down regulated genes.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Supplementary Table 3: Genes Only Influenced By
    Supplementary Table 3: Genes only influenced by X10 Illumina ID Gene ID Entrez Gene Name Fold change compared to vehicle 1810058M03RIK -1.104 2210008F06RIK 1.090 2310005E10RIK -1.175 2610016F04RIK 1.081 2610029K11RIK 1.130 381484 Gm5150 predicted gene 5150 -1.230 4833425P12RIK -1.127 4933412E12RIK -1.333 6030458P06RIK -1.131 6430550H21RIK 1.073 6530401D06RIK 1.229 9030607L17RIK -1.122 A330043C08RIK 1.113 A330043L12 1.054 A530092L01RIK -1.069 A630054D14 1.072 A630097D09RIK -1.102 AA409316 FAM83H family with sequence similarity 83, member H 1.142 AAAS AAAS achalasia, adrenocortical insufficiency, alacrimia 1.144 ACADL ACADL acyl-CoA dehydrogenase, long chain -1.135 ACOT1 ACOT1 acyl-CoA thioesterase 1 -1.191 ADAMTSL5 ADAMTSL5 ADAMTS-like 5 1.210 AFG3L2 AFG3L2 AFG3 ATPase family gene 3-like 2 (S. cerevisiae) 1.212 AI256775 RFESD Rieske (Fe-S) domain containing 1.134 Lipo1 (includes AI747699 others) lipase, member O2 -1.083 AKAP8L AKAP8L A kinase (PRKA) anchor protein 8-like -1.263 AKR7A5 -1.225 AMBP AMBP alpha-1-microglobulin/bikunin precursor 1.074 ANAPC2 ANAPC2 anaphase promoting complex subunit 2 -1.134 ANKRD1 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 1.314 APOA1 APOA1 apolipoprotein A-I -1.086 ARHGAP26 ARHGAP26 Rho GTPase activating protein 26 -1.083 ARL5A ARL5A ADP-ribosylation factor-like 5A -1.212 ARMC3 ARMC3 armadillo repeat containing 3 -1.077 ARPC5 ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa -1.190 activating transcription factor 4 (tax-responsive enhancer element ATF4 ATF4 B67) 1.481 AU014645 NCBP1 nuclear cap
    [Show full text]
  • Supplementary Table 2 Differentially Expressed Genes in PC3 Prostate Adenocarcinoma Cells 48 H After Transfection with Sirxfp1 Versus Sinc Control Sirna
    Supplementary Table 2 Differentially expressed genes in PC3 prostate adenocarcinoma cells 48 h after transfection with siRXFP1 versus siNC control siRNA. Genes with P<0.05 are shown Average fold change PROBE_ID TargetID Title (siRXFP1/siNC) ILMN_1757406 HIST1H1C histone cluster 1, H1c 2.358875 ILMN_1691846 G0S2 G0/G1switch 2 2.148632 ILMN_1706505 COL5A1 collagen, type V, alpha 1 2.030442 ILMN_1715684 LAMB3 laminin, beta 3 1.891462 ILMN_1809402 MAN2A1 mannosidase, alpha, class 2A, member 1 1.843399 ILMN_1666503 DENND2A DENN/MADD domain containing 2A 1.794946 ILMN_1746465 FJX1 four jointed box 1 (Drosophila) 1.777726 ILMN_1688670 CDCP1 CUB domain containing protein 1 1.743697 ILMN_1708341 PDZK1 PDZ domain containing 1 1.740739 ILMN_1658702 HIST1H2BJ histone cluster 1, H2bj 1.621722 ILMN_1756777 HBEGF heparin-binding EGF-like growth factor 1.594607 ILMN_1727315 DENND1A DENN/MADD domain containing 1A 1.581216 CKLF-like MARVEL transmembrane domain ILMN_1705442 CMTM3 containing 3 1.529026 estrogen receptor binding site associated, ILMN_1729144 EBAG9 antigen, 9 1.507585 ILMN_1666507 PLAUR plasminogen activator, urokinase receptor 1.480579 plakophilin 1 (ectodermal dysplasia/skin ILMN_1663454 PKP1 fragility syndrome) 1.475808 ILMN_1706643 COL6A3 collagen, type VI, alpha 3 1.47301 ILMN_1795055 LRRC3 leucine rich repeat containing 3 1.471709 ILMN_1722845 RAB3B RAB3B, member RAS oncogene family 1.432296 ILMN_1691508 PLAUR plasminogen activator, urokinase receptor 1.423904 ILMN_1703531 EDG3 sphingosine-1-phosphate receptor 3 1.421666 ILMN_1803728
    [Show full text]
  • Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent- Title Responsive Biomarker
    Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent- Title Responsive Biomarker Author(s) 山村, 宏江 Citation 北海道大学. 博士(工学) 甲第11137号 Issue Date 2013-09-25 DOI 10.14943/doctoral.k11137 Doc URL http://hdl.handle.net/2115/77180 Type theses (doctoral) File Information Hiroe_Yamamura.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Doctoral Thesis Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent-Responsive Biomarker Hiroe Hara-Yamamura Acknowledgement My doctoral research works presented here cannot be completed without a numerous number of tangible and intangible supports from my peers, my supervisor, instructors, friends, and family. I would first express my deepest gratitude to Prof. Satoshi OKABE for his technical advices and crisp ideas which often came to break the deadlock of my research progress, and for continued provision of another chance to me, even in the least fruitful season. Indeed, my three years in Prof. OKABE’s lab was “luxuri- ous” time in my life with a lot of supports, encouragements, and chances. In addition, I appreciate both Prof. Daisuke SANO and Dr. Satoshi ISHII for offering their insights on my experimental design and data analysis as well as giving me words of encouragements from time to time. Also, thank you to Prof. Takashi KUSUI from Toyama Prefectural University for his assistance to bioassay techniques and valuable discussion dur- ing my 1st year and 2nd year evaluation presentations. Furthermore, I would like to express my gratitude to specific efforts kindly provide by: Mr. Kenzo Kudo, Prof.
    [Show full text]
  • Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics
    ORIGINAL RESEARCH published: 03 February 2017 doi: 10.3389/fphar.2017.00023 Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics Michèle Rouleau, Yannick Audet-Delage, Sylvie Desjardins, Mélanie Rouleau, Camille Girard-Bock and Chantal Guillemette * Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec, QC, Canada The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs) significantly influences the bioavailability and biological responses of endogenous molecule substrates and xenobiotics including drugs. UGTs participate in the regulation of cellular homeostasis by limiting stress induced by toxic molecules, and by Edited by: controlling hormonal signaling networks. Glucuronidation is highly regulated at genomic, Yuji Ishii, transcriptional, post-transcriptional and post-translational levels. However, the UGT Kyushu University, Japan protein interaction network, which is likely to influence glucuronidation, has received Reviewed by: little attention. We investigated the endogenous protein interactome of human UGT1A Ben Lewis, Flinders University, Australia enzymes in main drug metabolizing non-malignant tissues where UGT expression is Shinichi Ikushiro, most prevalent, using an unbiased proteomics approach. Mass spectrometry analysis Toyama Prefectural University, Japan of affinity-purified UGT1A enzymes and associated protein complexes in liver,
    [Show full text]
  • Discovery of a Molecular Glue That Enhances Uprmt to Restore
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.17.431525; this version posted February 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Discovery of a molecular glue that enhances UPRmt to restore proteostasis via TRKA-GRB2-EVI1-CRLS1 axis Authors: Li-Feng-Rong Qi1, 2 †, Cheng Qian1, †, Shuai Liu1, 2†, Chao Peng3, 4, Mu Zhang1, Peng Yang1, Ping Wu3, 4, Ping Li1 and Xiaojun Xu1, 2 * † These authors share joint first authorship Running title: Ginsenoside Rg3 reverses Parkinson’s disease model by enhancing mitochondrial UPR Affiliations: 1 State Key Laboratory of Natural Medicines, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. 2 Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. 3. National Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, Chinese Academy of Science, Shanghai 201210, China 4. Shanghai Science Research Center, Chinese Academy of Sciences, Shanghai, 201204, China. Corresponding author: Ping Li, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. Email: [email protected], Xiaojun Xu, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. Telephone number: +86-2583271203, E-mail: [email protected]. bioRxiv preprint doi: https://doi.org/10.1101/2021.02.17.431525; this version posted February 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Association of Cnvs with Methylation Variation
    www.nature.com/npjgenmed ARTICLE OPEN Association of CNVs with methylation variation Xinghua Shi1,8, Saranya Radhakrishnan2, Jia Wen1, Jin Yun Chen2, Junjie Chen1,8, Brianna Ashlyn Lam1, Ryan E. Mills 3, ✉ ✉ Barbara E. Stranger4, Charles Lee5,6,7 and Sunita R. Setlur 2 Germline copy number variants (CNVs) and single-nucleotide polymorphisms (SNPs) form the basis of inter-individual genetic variation. Although the phenotypic effects of SNPs have been extensively investigated, the effects of CNVs is relatively less understood. To better characterize mechanisms by which CNVs affect cellular phenotype, we tested their association with variable CpG methylation in a genome-wide manner. Using paired CNV and methylation data from the 1000 genomes and HapMap projects, we identified genome-wide associations by methylation quantitative trait locus (mQTL) analysis. We found individual CNVs being associated with methylation of multiple CpGs and vice versa. CNV-associated methylation changes were correlated with gene expression. CNV-mQTLs were enriched for regulatory regions, transcription factor-binding sites (TFBSs), and were involved in long- range physical interactions with associated CpGs. Some CNV-mQTLs were associated with methylation of imprinted genes. Several CNV-mQTLs and/or associated genes were among those previously reported by genome-wide association studies (GWASs). We demonstrate that germline CNVs in the genome are associated with CpG methylation. Our findings suggest that structural variation together with methylation may affect cellular phenotype. npj Genomic Medicine (2020) 5:41 ; https://doi.org/10.1038/s41525-020-00145-w 1234567890():,; INTRODUCTION influence transcript regulation is DNA methylation, which involves The extent of genetic variation that exists in the human addition of a methyl group to cytosine residues within a CpG population is continually being characterized in efforts to identify dinucleotide.
    [Show full text]